Syndax Pharmaceuticals, Inc.
SNDX
$11.05
-$0.28-2.47%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 23.68M | 16.00M | 3.50M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.68M | 16.00M | 3.50M | -- | -- |
| Cost of Revenue | 190.12M | 174.88M | 145.03M | 131.76M | 131.76M |
| Gross Profit | -166.44M | -158.88M | -141.53M | -131.76M | -131.76M |
| SG&A Expenses | 120.88M | 105.97M | 92.13M | 77.98M | 66.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 363.35M | 337.21M | 291.49M | 263.45M | 229.95M |
| Operating Income | -339.67M | -321.21M | -287.99M | -263.45M | -229.95M |
| Income Before Tax | -318.76M | -297.06M | -264.08M | -240.63M | -209.36M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -318.76 | -297.06 | -264.08 | -240.63 | -209.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -318.76M | -297.06M | -264.08M | -240.63M | -209.36M |
| EBIT | -339.67M | -321.21M | -287.99M | -263.45M | -229.95M |
| EBITDA | -339.66M | -321.20M | -287.98M | -263.44M | -229.94M |
| EPS Basic | -3.73 | -3.63 | -3.38 | -3.22 | -2.96 |
| Normalized Basic EPS | -2.33 | -2.27 | -2.11 | -2.01 | -1.85 |
| EPS Diluted | -3.73 | -3.64 | -3.38 | -3.23 | -2.97 |
| Normalized Diluted EPS | -2.33 | -2.27 | -2.11 | -2.01 | -1.85 |
| Average Basic Shares Outstanding | 341.71M | 328.44M | 312.86M | 297.23M | 281.45M |
| Average Diluted Shares Outstanding | 341.71M | 328.44M | 312.86M | 297.23M | 281.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |